Copyright: © 2024 The Author(s). Published by Elsevier Ltd.

Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking up wins against placebo and AstraZeneca’s Farxiga to stay on track to seek ...

Share on Pinterest A new study found that GLP1-RA medications may help lower the risk of a cardiovascular event in people with type 2 diabetes. Getty Images Researchers say GLP-1 drugs prescribed for ...

After beating Novo Nordisk’s semaglutide last month, Lilly’s much anticipated oral candidate orforglipron has taken down AstraZeneca’s Farxiga in a head-to-head trial. Eli Lilly’s oral GLP-1 ...

Eli Lilly released the results of two new Phase 3 trials of an experimental GLP-1 pill that the company says could become a “foundational treatment” for type 2 diabetes. The medicine, orforglipron, ...

This article is part of “Innovations In: Type 1 Diabetes,” an editorially independent special report that was produced with financial support from Vertex. A little more than a century ago a diagnosis ...

This article is part of “Innovations In: Type 1 Diabetes,” an editorially independent special report that was produced with financial support from Vertex. On one wall of endocrinologist Kevan Herold’s ...

Oct 10 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has decided to discontinue its cell therapy research and development efforts, a spokesperson for the Danish drugmaker told Reuters on Friday.

Novo Nordisk is ending all work in cell therapy, including a Type 1 diabetes program, amid CEO Maziar Mike Doustdar's reorganization. As part of the move, the company is laying off nearly all of the ...

aRenal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK ...

Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks the cells that produce insulin—a critical hormone that regulates blood sugar in the body. Scientists at Scripps ...